Oxford Biomedica

Investment area

Growth Investments



Date of investment

April 2019

Oxford Biomedica is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases.

Visit site


Robert Ghenchev

Managing Partner

Departments: Growth Investments, Novo Holdings Equity US Inc., Life Sciences Operating Committee

Robert joined Novo Holdings in January 2018 and serves as a Managing partner and head of  Growth Investments.

Before joining Novo Holdings, Robert was a Senior Vice President at Moelis & Company in London where he focused on mergers and acquisitions within the Healthcare Industry. Prior to Moelis, Robert was part of the UK Mergers & Acquisitions team at Deutsche Bank in London.

Robert holds a J.Hons. B.A. degree in Finance and Economics from McGill University and a M.Sc. degree in Financial Economics from the University of Oxford.